None

The Babraham Institute Announces the Formation of Babraham Commercialisation Services Ltd (News)

20 May 2013: Cambridge, UK - The Babraham Institute has announced the formation of a new wholly-owned trading arm, Babraham Commercialisation Services Ltd (BCS), to support its Knowledge Exchange and...

Commercialisation of Biosimilars 2012.

Speed-to-market is one of the key concerns for any biosimilar company looking for expansion. By 2015, sales of biosimilars are expected to reach between USD 1.9 to 2.6 billion. To be part of this ti...

CPhI to Hold Key Conference on the Commercialisation of Biosimilars

BANGALORE, India, September 21, 2012 /PRNewswire/ -- Speed-to-market is one of the key concerns for any biosimilar company looking for expansion. By 2015, sales of biosimilars are expected to reach b...

NIPER─Hyderabad to organise workshop on D2 @ C2 from August 30

The National Institute of Pharmaceutical Education and Research (NIPER), Hyderabad is organising a three─day workshop on Drug Development: Conceptualisation to Commercialisation (D2 @ C2).

AstraZeneca and BIND Therapeutics Announce Worldwide Development and Commercialisation Agreement for Cancer Nanomedicine (News)

22 April 2013: Cambridge, UK & Cambridge, MA, USA - AstraZeneca and BIND Therapeutics announced today that they have entered into a strategic collaboration to develop and commercialise an ...

Series A brings in $4mm so far for [Heart Metabolics]

Cardiovascular drug developer [Heart Metabolics Ltd.] has raised $4mm with the closing of the first tranche of a planned $6mm Series A venture round. Trans Tasman Commercialisation Fund and AshHill In...

ithree institute at UTS adds momentum to medical research commercialisation fund (MRCF)

Monday 17 October 2011, Sydney ... A collaborative effort by medical research teams in four states to commercialise new research is gaining momentum with the addition of the ithree institute at t...

MRCF launches [Helmedix] with $A1.25mm

The Medical Research Commercialisation Fund (MRCF; managed by Brandon Capital Partners) has seeded [Helmedix Pty. Ltd.] with a $A1.25mm ($1.29mm) investment. Helmedix was launched with the investment...

Optimal balance of efficacy and tolerability of oral triptans and telcagepant: a review and a clinical comment.

Dose-response curves for headaches relief and adverse events (AEs) are presented for five triptans: sumatriptan, zolmitriptan, naratriptan, almotriptan, and frovatriptan, and the CGRP antagonist telca...

RAMP-ing up Class-B GPCR ECD Structural Coverage.

The cocrystal structure of the heterodimer GPCR extracellular domain complex of the CGRP receptor (CLR and RAMP1) has been determined in an apo form and with two different antagonists olcegepant and t...

Commercialisation of Regenerative Medicine: Learning from Spin-Outs.

'Commercialisation of your regenerative medicine research; lessons from spin out successes' was hosted by Oxbridge Biotech Roundtable (OBR) (Oxford, UK) at the University of Oxford in February 2013, a...

Acute Migraine Therapy: New Drugs and New Approaches.

OPINION STATEMENT: The conceptual shift of our understanding of migraine from a vascular disorder to a brain disorder has dramatically altered the approach to the development of new medicines in the f...

Asymmetric hydrogenation of protected allylic amines.

A general method for the enantioselective hydrogenation of protected allylic amine derivatives is described. This procedure relies on the generation of a cationic ruthenium complex with the axially ch...